Moreover, several studies have reported successful design of a complex of ELP-drug/peptide conjugates, such as ELPs conjugated with doxorubicin for efficient tumor or cancer targeting and drug delivery, [36,37], ELPs with vascular endothelial growth factor (VEGF) for treatment of preeclampsia [38] and renovascular disease [39], ELPs conjugated with paclitaxel for breast cancer treatment by inhibiting the proliferation of the MCF-7 cell line, stabilizing microtubules structures, arresting cell division at the G2/M stage and inducing apoptosis [40]. The gene discussed is VEGFA; the disease is breast cancer.